Yet an­oth­er NASH de­feat for Gilead as 3-drug cock­tail fiz­zles. Now one an­a­lyst says it's time for a change-up

6 years ago
R&D

Bio­Marin eyes FDA ap­proval as PhI­II re­sults emerge in most com­mon form of dwarfism

6 years ago
R&D

Wave's Duchenne pro­gram comes to a screech­ing halt — now all eyes will be on Hunt­ing­ton's

6 years ago
R&D

Rare skin dis­ease biotech eyes $16 mil­lion IPO as tri­al re­sults come in and cash runs out

6 years ago
R&D

BeiGene's BTK in­hibitor fails to beat mar­ket leader Im­bru­vi­ca in key head-to-head study

6 years ago
R&D
China

Paul Bion­di is jump­ing from Bris­tol-My­ers to the elite team man­ag­ing Flag­ship's star­tups — with new­co plans of his ...

6 years ago
R&D

UK an­titrust watch­dog clears Roche/Spark deal — but what is the FTC think­ing?

6 years ago
Deals
Cell/Gene Tx

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nals big trou­ble for a lit­tle ...

6 years ago
R&D

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

6 years ago
Cell/Gene Tx

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

6 years ago
Pharma
FDA+

FDA ex­pert pan­el unan­i­mous­ly rec­om­mends ap­proval for Hori­zon Ther­a­peu­tics eye drug

6 years ago
FDA+

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

6 years ago
Biotech Voices

Shehnaaz Suli­man dives back in­to Alzheimer's at Alec­tor; Pyx­is re­cruits Spring­Works founder Lara Sul­li­van as CEO

6 years ago
Peer Review

More ques­tions than an­swers for bio­phar­ma af­ter UK elec­tion; In­ter­cept gets FDA ad­vi­so­ry date, and a PDU­FA de­lay

6 years ago
News Briefing

PhII fail­ure in rare neu­rode­gen­er­a­tive dis­ease? No mat­ter, Bio­gen will mo­tor on in Alzheimer's

6 years ago
R&D

A USP­TO le­gal ad­vis­er is off con­tro­ver­sial Gilead HIV case af­ter ac­tivists al­lege tweets show bias

6 years ago
Pharma

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete ...

6 years ago
R&D

What's next for Sarep­ta? A third DMD ap­proval, an­a­lysts pre­dict

6 years ago
FDA+

Roche's triplet in­volv­ing Tecen­triq clears the PFS bar for melanoma when added to BRAF/MEK com­bo

6 years ago
R&D
Pharma

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

6 years ago
R&D
FDA+

Stephen Hahn con­firmed as new FDA chief

6 years ago
FDA+

Bris­tol-My­er­s' strat­e­gy, BD chief Paul Bion­di ex­it­ed the com­pa­ny — just ahead of the $74B Cel­gene deal close

6 years ago
People

House pass­es Pelosi drug pric­ing bill on par­ty-line vote

6 years ago
Pharma

Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

6 years ago
Cell/Gene Tx
First page Previous page 884885886887888889890 Next page Last page
A service from the Financial Times